Aldehyde dehydrogenase is regulated by β-Catenin/TCF and promotes radioresistance in prostate cancer progenitor cells

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1482-1494

  Cojoc, Monica ^a   Peitzsch, Claudia ^a   Kurth, Ina ^a   Trautmann, Franziska ^a   Kunz Schughart, Leoni A ^a   Telegeev, Gennady D ^b   Stakhovsky, Eduard A ^c   Walker, John R ^d   Simin, Karl ^e   Lyle, Stephen ^e   Fuessel, Susanne ^f   Erdmann, Kati ^f   Wirth, Manfred P ^f   Krause, Mechthild ^a,f,g,h   Baumann, Michael ^a,f,g,h   Dubrovska, Anna ^a,h  

^a Helmholtz Zentrum Dresden Rossendorf   (Germany)

^b INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^c NATIONAL CANCER INSTITUTE   (Ukraine)

^d GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA CATENIN; DIETHYLAMINOBENZALDEHYDE; GALIELLALACTONE; RADIOSENSITIZING AGENT; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; ALDH1A1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; TRANSCRIPTOME;

ALDH1A1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CONTROLLED STUDY; DNA REPAIR; DRUG EFFECT; ENZYME ACTIVITY; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; X RAY; ANIMAL; CANCER TRANSPLANTATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ALDEHYDE DEHYDROGENASE; ANIMALS; BETA CATENIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; TRANSCRIPTOME; WNT SIGNALING PATHWAY;

EID: 84930019376     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1924     Document Type: Article

References (50)

1. Horwich A, Parker C, Reijke T, Kataja V. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;Suppl 6:vi106-14.
2. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, et al. Prostate cancer, version 1.2014. J Natl Compr Canc Netw 2013;11: 1471-9.
3. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomizedtrial comparing conventional-dosewithhigh-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106-11.
4. Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DYT, Horwitz EM, Hanks GE, et al. Radiotherapy doses of 80Gy and higher are associatedwith lower mortality in men with gleason score 8 to 10 prostate cancer. Int J Radiat Oncol 2012;82:1949-56.
5. Johansson S, Aström L, Sandin F, Isacsson U, Montelius A, Turesson I. Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized. Prostate Cancer 2012;2012:654861.
6. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008;8:545-54.
7. Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol 2013;108:378-87.
8. Bütof R, Dubrovska A, Baumann M. Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol 2013;108: 388-96.
9. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-8.
10. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-51.
11. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+a2b1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67:6796-805.
12. Dubrovska A, Elliott J, Salamone RJ, Kim S, Aimone LJ, Walker JR, et al. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin Cancer Res 2010;16: 5692-702.
13. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007;46:1-14.
14. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
15. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci 2009;106:268-73.
16. Asuthkar S, Gondi CS, Nalla AK, Velpula KK, Gorantla B, Rao JS. Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/b-catenin signaling is enhanced in irradiated medulloblastoma cells. J Biol Chem 2012;287:20576-89.
17. Ghisolfi L, Keates AC, Hu X, Lee D, Li CJ. Ionizing radiation induces stemness in cancer cells. PLoS One 2013;7:e43628.
18. Xu N, Lao Y, Zhang Y, Gillespie DA. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012;2012:951724.
19. Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. In: Bjergbæk L, editor. DNA repair protocols. New York: Humana Press; 2012. p. 613-26.
20. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-83.
21. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501-13.
22. Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol 2013;25:254-64.
23. Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol 2010;2: a002915.
24. Krasnapolski A, Todaro MB, de Kier Joffe E. Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient? Curr Pharm Biotechnol 2011;2:1891-9.
25. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002;22:1172-83.
26. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
27. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol 2011;18:867-74.
28. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012;22:457-72.
29. Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett 2013;341:63-72.
30. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012;22:194-207.
31. Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, et al. E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol 2011;99:392-7.
32. Bonkhoff H. Factors implicated in radiation therapy failure and radio-sensitization of prostate cancer. Prostate Cancer 2012;2012:593241.
33. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65.
34. Baumann M, Krause M, Zips D, Eicheler W, Dörfler A, Ahrens J, et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squa-mous cell carcinoma in the nude mouse. Int J Radiat Biol 2003;79: 547-59.
35. Krause M, Prager J, Zhou X, Yaromina A, Dörfler A, Eicheler W, et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells? Radiother Oncol 2007;83:316-25.
36. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012;198:281-93.
37. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010;28:4006-12.
38. Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer 2004;43:71-4.
39. Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, et al. Pre-treatment risk stratification of prostate cancer patients: acritical review. Can Urol Assoc J 2012;6:121-7.
40. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Heal Technol Assess Winch Engl 2009;13:iii, xi-xiii 1-219.
41. Magnen CL, Bubendorf L, Rentsch CA, Mengus C, Gsponer JR, Zellweger T, et al. Characterization and clinical relevance of ALDHbright populations in prostate cancer. Clin Cancer Res 2013;19:5361-71.
42. Harada H. How can we overcome tumor hypoxia in radiation therapy? J Radiat Res (Tokyo) 2011;52:545-56.
43. Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L, et al. Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells 2010;28: 1918-29.
44. Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang YJ, et al. HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ 2012;19: 284-94.
45. Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res 2012;18: 6634-47.
46. Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, et al. Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget 2014;5:3743-55.
47. Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A 2013; 110:8644-9.
48. Pate KT, Stringari C, Sprowl-Tanio S, Wang K, TeSlaa T, Hoverter NP, et al. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J 2014;33:1454-73.
49. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2012;4:e875.
50. Chang L, Graham PH, Hao J, Bucci J, Cozzi PJ, Kearsley JH, et al. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev 2014;33:469-96.